Osteoarthritis (OA) is a chronic, painful disease affecting articulating joints in man and animals. It is characterized by cartilage breakdown, bone remodeling, osteophyte formation and joint inflammation. Currently used non-steroidal anti-inflammatory drugs for the management of OA are known to have deleterious side effects. To address the need for alternatives, we evaluated the anti-inflammatory effects of a combination of avocado/soybean unsaponifiables (ASU), glucosamine (GLU) and chondroitin sulfate (CS) by measuring chemokine MCP-1 (monocyte chemoattractant protein 1, CCL2) and prostaglandin E-2 (PGE 2 ) in stimulated chondrocytes. As the only cellular constituents of cartilage, chondrocytes are the source of pro-inflammatory mediators that play critical roles in the pathogenesis of OA. Chondrocytes were incubated: with: 1) control media, 2) [ASU + GLU + CS] combination, or 3) Phenylbutazone (PBZ) for 24 hours. Cells were next stimulated with IL-1β or LPS for another 24 hrs. MCP-1 and PGE 2 from supernatants were quantitated by immunoassay. Another set of chondrocytes seeded in chamber slides were stimulated with IL-1β for 1 hour and then immunostained for NF-κB. Chondrocytes stimulated with IL-1β or LPS significantly increased MCP-1 and PGE 2 production which were significantly reduced after treatment with [ASU + GLU + CS]. In contrast, PBZ significantly reduced PGE 2 but not MCP-1 production. IL-1β stimulation induced nuclear translocation of NF-κB, which The present study provides evidence that the production of MCP-1 by chondrocytes can be inhibited by the combination of [ASU + GLU + CS] but not by PBZ. In contrast, PGE 2 production was inhibited by either treatment suggesting that the production of MCP-1 and PGE 2 could be independently regulated. The finding of distinct effects of [ASU + GLU + CS] on MCP-1 and PGE 2 synthesis supports a scientific rationale for a multimodal treatment approach in the management of OA.
Introduction
Osteoarthritis (OA) is a painful, chronic degenerative disease which affects the quality of life in both man and animals [1] . OA is characterized by cartilage breakdown, bone remodeling, osteophyte formation and joint inflammation.
Humans and animals such as horses afflicted with OA suffer from debilitating morbidity [2] . OA in horses accounts for substantial monetary loss in the equine industry. It is estimated that 60% of lameness problems in horses are due to OA [3] . Approximately one third of 2 and 3-year old thoroughbred racehorses have macroscopic and histologic changes of the metacarpophalangeal joint associated with OA [4] . Humans and horses have similar joint volume, structure and biomechanical function [5] [6] . Their articular cartilage also exhibits similar cellular and molecular characteristics [5] [6] . Because of their common structural, functional and cellular characteristics, horses have been used as an in vivo model for studying human OA. Equine joint tissues such as cartilage and their constituent chondrocytes have also been beneficial as models for in vitro studies [7] [8] [9] [10] [11] .
Pro-inflammatory mediators including prostaglandins (PG), cytokines, and chemokines play important roles in the pathogenesis of OA [12] - [26] . PGE 2 , interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α are well documented mediators of chronic pain and cartilage degradation in OA [12] - [26] . More recently, chemokines including MCP-1 (CCL2) and their receptors have been recognized as important players in OA pathogenesis [17] - [26] . Stimulation of human chondrocytes with IL-1β or TNF-α results in upregulation of MCP-1 gene expression compared to untreated controls [21] . In addition, there is evidence that MCP-1 contributes to cartilage matrix degeneration by increasing secretion of matrix metalloproteinase (MMP)-3 by chondrocytes [18] . MCP-1 as a key mediator of chronic pain has also been reported. Knockout mice with deleted MCP-1 receptor have been used to define this chemokine as a factor in nociception. While acute pain behavior is relatively unchanged in these animals, hyper- [21] . Administration of exogenous MCP-1 is seen to increase firing of dorsal root ganglia neurons, leading to neuronal hyperexcitability and neuropathic pain [22] . Studies also reinforced the role of MCP-1 as a mediator of osteoarthritic pain [17] - [26] . In addition, increased levels of MCP-1 in situ appear to correlate with the severity of the disease. These observations strengthen the possibility that MCP-1 plays a role in chronic pain and hyperalgesia.
Evidence supporting the role of pro-inflammatory molecules such as prostaglandins, cytokines and chemokines in the pathogenesis of OA led to the use of non-steroidal anti-inflammatory drugs (NSAIDs). These drugs help ease the pain and alleviate symptoms in OA patients but do not modify disease progression. Moreover, NSAIDs are associated with deleterious side effects affecting cardiovascular, gastrointestinal, renal and hepatic systems [27] . NSAIDs that ablate PGE 2 production also disrupt bone healing and fracture repair [28] [29]
[30]. Awareness of the adverse effects of NSAIDs has prompted the need to evaluate complementary and alternative agents for the safe management of OA.
Non-pharmacologic agents that have been evaluated include glucosamine (GLU), chondroitin sulfate (CS) and avocado/soybean unsaponifiables (ASU) alone or in combination. ASU, GLU and CS have been documented to reduce inflammation in vitro [9] [10] [11] , [31] - [38] , and in vivo [39] - [46] . These agents have been reported to ameliorate OA in man and animals with minimal adverse side effects [39] - [46] . The molecular mechanism behind the beneficial effects of ASU, GLU and CS has been attributed to their ability to inhibit activation of NF-κB transcription factor [47] - [52] . When activated, NF-κB translocates from the cytoplasm to the nucleus which induces the expression of pro-inflammatory genes and catabolic enzymes that break down cartilage [47] - [52] .
To address the need for safe alternative anti-inflammatory agents, this study was conducted to determine whether the combination of ASU, GLU and CS will inhibit production of key inflammatory mediators: MCP-1 and PGE 2 . We also determined whether production of these pro-inflammatory mediators will similarly be inhibited by the NSAID, phenylbutazone (PBZ 
Materials and Methods

Isolation of Equine Chondrocytes
Treatment Design
Cells were seeded in flasks, and allowed to grow to confluency in control media consisting of Dulbeccos' Modified Eagle's basal medium (Sigma; St. Louis, MO, USA) supplemented with 10% v/v fetal bovine serum (Gemini Bio-Products; Woodland, CA, USA), 300 mg/ml L-glutamine (Sigma), 30 mg/ml antibiotic/antimycotic (Sigma), and 3.7 g/L sodium bicarbonate (Sigma), pH 7.4at 37°C, 5% CO 2 [9] . Chondrocytes were used at passage 2 -4. Chondrocytes were seeded in 6-well plates at 5 × 10 6 cells/well, and incubated at 37˚C, 5% CO 2 for 24 hours.
Chondrocytes were then pre-treated with 1) control media, 2) [ASU (NMX1000®, 8.3 µg/mL) + GLU (FCHG49®, 11 µg/mL) + CS (TRH122®, 20 µg/mL)] (Nutramax Laboratories, Inc., Edgewood, MD, USA), or 3) PBZ (4 µg/mL, Sigma-Aldrich, St. Louis, MO, USA) for an additional 24 hours. The concentrations of ASU, GLU, CS and PBZ used in the present study were previously reported to have significant anti-inflammatory effects and are clinically relevant [39] - [46] . Cells were then activated for 24 hours with IL-1β (10 ng/mL, R&D Systems, Minneapolis, MN, USA) or lipopolysaccharide (LPS, 1 ng/mL, Sigma-Aldrich). Supernatant was collected and stored at −80˚C until assays were performed. Nine chondrocyte lines at passage 2 -4 from different horses were used and experiments were performed in triplicate.
Collagen and Aggrecan Immunofluorescence
Chondrocyte phenotype was characterized by immunofluorescence staining for collagen and aggrecan [9] . Chondrocytes were seeded at 1 × 10 4 cells/well on Slides were washed 3 times with PBS and nuclei were stained with DAPI (Gibco Invitrogen) for 30 minutes as described above. Staining was analyzed using a Nikon epifluorescence TE 200 microscope and digital images were captured with a digital camera (Nikon Spot Camera, USA).
Determination of NF-κB Nuclear Translocation Using Immunofluorescence
Chondrocytes were seeded on 8-well chamber slides as described above. Cells were incubated at 37˚C, 5% CO 2 overnight with 1) control media, 2) [ASU (NMX1000®, 8.3 µg/mL) + GLU (FCHG49®, 11 µg/mL) + CS (TRH122®, 20 µg/mL)], or 3) PBZ (4 µg/mL). Cells were activated for 1 hour with IL-1β (10 ng/mL). Rabbit anti-NF-κB (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was applied to the cells and incubated overnight at 4˚C. Slides were washed with 1x PBS, and a secondary donkey anti-rabbit IgG antibody labeled with Alexa Fluor-488 (Invitrogen) was applied for 2 hours. Cells were washed and analyzed using a Nikon epifluorescence TE 200 microscope and digital images were captured with a digital camera (Nikon Spot Camera, USA).
MCP-1 and PGE2 Immunoassay (ELISA)
MCP-1 and PGE 2 concentrations were determined in cell culture supernatant using commercially available ELISA kits (Equine CCL2 (MCP-1) VetSet, Kingfisher Biotech Inc., St. Paul, MN, USA and Prostaglandin E2 Parameter Assay Kit, R&D Systems). All assays were run according to manufacturers' instructions and a standard was run in parallel to samples during each assay. Optical density was measured immediately using the SpectraMAX 340 microplate reader (Molecular Devices, Sunnyvale, CA, USA) at 450 nm with wavelength correction at 540 nm.
Statistical Analysis
Pair-wise multiple comparisons were performed using one-way ANOVA, Tukey post-hoc using SigmaStat statistical software (Windows Version 3.11), where p < 0.05 was considered statistically significant.
Results
Chondrocyte Phenotype Characterization
Chondrocytes in monolayer culture showed immunostaining for collagen 
Stimulation of Chondrocyte MCP-1 and PGE2 Production by IL-1β and LPS
Stimulation of MCP-1 and PGE 2 production by IL-1β was confirmed in chondrocyte cell lines 1 -3 ( Figure 2 ) and in chondrocytes cell lines 4 -6 by LPS ( Figure 3 ). Untreated control chondrocytes produced MCP-1 concentrations ranging from 10 -25 × 10 3 pg/ml which significantly increased 5 -7 times with IL-1β stimulation, p < 0.001 ( Figure 2 , left panel). Lines 1 -3 also produced variable baseline levels of PGE 2 ranging from 1 -16 × 10 2 pg/ml which significantly 
Effect of PBZ or [ASU + GLU + CS] on MCP-1 and PGE2 Production
Pre ( Figure 5 ). PBZ increased MCP-1 production slightly in all cultures; however this was not statistically significant ( Figure 5 ).
Effect of PBZ or [ASU + GLU + CS] on NF-κB Nuclear Translocation
The association between inhibition of MCP-1 and PGE 2 production and suppression of NF-κB activation was analyzed using immunostaining. Chondrocytes 
Discussion
The principal finding of the present study is that [ASU + GLU + CS] inhibits MCP-1 and PGE 2 production whereas PBZ ablates PGE 2 levels but has minimal effect on MCP-1 levels. We used equine chondrocytes in monolayer culture since they display phenotypic changes similar to those of osteoarthritic cartilage. Chondrocytes shift from producing the articular cartilage phenotype marker type II collagen to the fibroblastic-osteoblastic type I collagen observed in osteoarthritic cartilage. At passage 2 -4, some chondrocytes produce type II while some produce either type I collagen alone or both (Figure 1 ). These chondrocyte cultures also showed robust response to IL-1β and LPS stimulation indicated by significant increase in MCP-1 andPGE 2 production confirming earlier reports (Figures 2, Figure 3 ). The finding that [ASU + GLU + CS] significantly suppressed but did not totally ablate MCP-1 and PGE 2 production suggests that this compound could minimize disruption of physiologic functions of these molecules ( Figure 4 , Figure   5 ). It has been reported that NSAIDs that totally block PGE 2 production interfere with bone healing and fracture repair [28] [47]- [52] . NF-κB is well known as a critical regulator of the inflammatory re- 
Conclusion
This study provides evidence that the inhibition of MCP-1 can be a specific target for therapeutic intervention. Targeting 
